The Evolution of Crop Protection — Moving from…

Resistance, regulation, and a historic patent cliff are eroding synthetic chemistry's economics. Flagship is building an ecosystem of platforms — peptides, RNA, endophytes — engineered to compound value.

Every season, farmers wage a quiet war on a trillion-dollar battlefield. Insects, fungal pathogens, viruses, and weeds destroy an estimated 20–40% of global crop production annually. These losses are worth hundreds of billions of dollars; a sum that could increase as the changing climate expands pest ranges and intensifies disease pressure.

For seventy years, synthetic chemistry has been agriculture's primary line of defense. While this approach has been remarkably effective, responsible for building the modern crop protection industry, it is now straining under the weight of four converging forces:

regulatory timelines that have made innovation slower and costlier than ever
pests that are evolving resistance faster than new chemistry can be invented
a patent cliff that is stripping the economics out of the very molecules that fund the industry's innovation engine
consumers who increasingly reject chemical residues on their food.

The result is a widening gap between what farmers need and what the industry can deliver. Closing that gap will require more than incremental improvements to synthetic chemistry. It will require fundamentally new modalities — and a fundamentally new way of building companies to deliver them.

The innovation engine is slowing down

Bringing a new synthetic crop protection active ingredient to market today takes roughly a dozen years and approximately $300 million in discovery, development, and registration costs — figures that have climbed steadily for decades. A company beginning discovery today is betting on the regulatory, agronomic, and consumer landscape of the late 2030s. Few industries ask innovators to take these long wagers.

The consequences are visible across the industry. The number of new active ingredients reaching the market has declined, and the chemistry that does emerge is increasingly concentrated in a handful of mode-of-action classes. Meanwhile, the existing toolbox is shrinking from the other end: Re-registration reviews in Europe and elsewhere are removing long-standing products from the market, often faster than replacements arrive. Farmers in many geographies now face pests and diseases for which no effective, registered solution exists.

This is not a criticism of regulators who are responding to legitimate questions about environmental and human health. It is a structural observation: A system in which innovation takes twelve years and deregistration can happen much faster will, by arithmetic alone, leave farmers with fewer tools each year.

The resistance treadmill

The second pressure is biological. Resistance is the predictable consequence of exposing vast pest populations to a limited set of modes of action, season after season. Hundreds of insect and mite species have documented resistance to major insecticide classes; fungicide resistance has eroded the utility of entire chemistries; herbicide-resistant weeds now infest hundreds of millions of acres worldwide. Each new resistant population increases selection pressure on the remaining effective products, accelerating the cycle.

The industry's traditional answer — rotate chemistries, stack modes of action — depends on a steady supply of novel modes of action. But as noted above, that supply is thinning. Resistance management is becoming a game of musical chairs in which chairs are being removed at both ends.

Synthetic crop protection is living through its own version of pharma's patent cliff — and the steepest section lies directly ahead.

The patent cliff: The economics of chemistry are eroding

The third force is financial, and it may prove the most consequential for the industry's structure. Synthetic crop protection is living through its own version of pharma's patent cliff — and the steepest section lies directly ahead.

The industry is already predominantly generic: Well over half of global crop protection sales by value come from off-patent molecules, and more than a hundred active ingredients have lost patent protection over the past fifteen years. But the wave now cresting is different in quality, not just quantity. The molecules coming off patent between now and 2030 include some of the most valuable chemistries ever commercialized.

The consequences ripple through the entire innovation system. For the research-based multinationals, patent expiry means margin compression on exactly the products whose profits were meant to fund the next decade of discovery. The economics of inventing new synthetic chemistry deteriorate with each cycle: A twelve-year, $300 million development effort now buys only eight to ten years of market exclusivity before generic manufacturers — who bear none of the discovery cost — move in at a fraction of the price. The rational response, visible in every major agrochemical company's strategy, is to redirect capital away from de novo synthetic discovery and toward formulations, mixtures, digital tools, and — tellingly — biologicals.

For farmers, the cliff cuts both ways — cheaper generics in the near term, but a hollowed-out pipeline in the long term. And for the resistance problem, commoditization makes things worse — cheap, abundant generic supply encourages heavier and less disciplined use of aging modes of action, accelerating the very resistance that makes those molecules obsolete.

The industry needs new engines of differentiated, protectable innovation — and it needs them on faster development cycles than chemistry can offer.

Consumers have changed the demand equation

At the same time, the ultimate customer of agriculture — the consumer — has changed. Surveys consistently show that pesticide residues rank among consumers' top food safety concerns, and that concern is reshaping the market well upstream of the grocery aisle. Food companies and retailers are imposing residue standards stricter than legal maximum residue limits (MRLs). Export markets are tightening MRL enforcement, turning residue management into a trade issue. And the growth of organic and "clean label" categories signals a durable willingness to pay for food perceived as free of synthetic chemicals.

Whether every consumer concern is scientifically proportionate is, in a sense, beside the point. Perception is now a market force. Growers are being asked — by their buyers, not just their regulators — to produce more food with fewer detectable chemical inputs. That demand cannot be met by chemistry alone.

Just as important in a post-patent-cliff world, platform-based biologicals offer fundamentally better innovation economics.

Biologicals: From niche to necessity

Against this backdrop, biological crop protection — products derived from or inspired by nature, including microbes, peptides, RNA, natural extracts, and beneficial organisms — has moved from the industry's periphery toward its center. The logic is compelling. Biologicals typically offer novel modes of action that can break resistance cycles; residue and toxicity profiles that align with consumer and regulatory expectations; and, in many jurisdictions, materially faster and less expensive registration pathways than synthetic chemistry.

Just as important in a post-patent-cliff world, platform-based biologicals offer fundamentally better innovation economics. Development cycles are shorter, and capital intensity per product is lower. And their differentiation is durable, rooted in proprietary platforms, strains, sequences, and delivery technologies rather than in a single expiring composition-of-matter patent. It is no surprise that the biologicals segment is growing at multiples of the overall crop protection market's rate, or that every major agrochemical company has made biologicals a strategic priority.

But candor is warranted: the first generation of biologicals often underdelivered. Products struggled with field consistency, shelf life, and efficacy under real-world conditions. Farmers learned to be skeptical — and that skepticism, once earned, is slow to fade. The lesson is not that biologicals cannot work; it is that making them work requires deep platform science, precision delivery, and rigorous agronomic validation, not simply fermenting a microbe and putting it in a jug.

Flagship's answer: An ecosystem of modalities

This is where Flagship Pioneering's approach to company creation becomes a strategic advantage. Because Flagship originates and builds companies from first principles, we have been able to construct something no single startup — and arguably no incumbent — possesses. We have created an ecosystem of crop protection companies, each built on a distinct technology platform and biological modality, that can operate independently and in concert.

Invaio Sciences harnesses peptides — nature's own precision molecules — coupled with proprietary delivery technologies that place active ingredients exactly where they are needed. Peptides offer exquisite target specificity, meaning they can control a pest while sparing pollinators and beneficial insects. And they degrade naturally, leaving no persistent residues. Programmable delivery systems enable the efficient and effective use of these novel bioactives and ensure they go directly where and when they are needed. Invaio’s solutions demonstrate the performance of synthetic chemicals with the environmental benefits of biologicals, by design.

Terrana Biosciences builds on one of biology's most elegant mechanisms: RNA. RNA-based crop protection can be designed to silence essential genes in a specific pest or pathogen — and only that pest or pathogen — by giving plants the necessary molecular tools to protect themselves. This is programmable specificity: As the target evolves, the RNA sequence can be updated, offering a fundamentally new answer to the resistance treadmill. And because RNA is transient and naturally degraded in the environment, it directly addresses residue and ecotoxicity concerns.

ENAI works with endophytes — the microbes that live within plant tissues and have co-evolved with crops over millions of years. Rather than applying protection from the outside, endophytes enlist the plant's own microbiome to defend against pests and pathogens and to strengthen resilience against stress. Built on one of the world's most-diverse collections of characterized plant-associated microbes and years of field data, including 7,500 field trials in row crops, this platform brings protection that is, quite literally, alive inside the crop.

The power of the ecosystem

Each of these companies is a formidable platform in its own right. Together, they are also a combinatorial system for crop protection.

Peptides, RNA, and endophytes act through entirely different mechanisms, which means they can be layered to create multi-mode-of-action solutions with built-in resistance management — the biological equivalent of combination therapy in medicine. A delivery technology developed for one modality can carry another. An endophyte can be a chassis; an RNA or peptide can be a payload. Insights about a target pest generated in one company inform target selection in the others. And because each platform can generate many products across many crops and geographies, the ecosystem compounds: Every new product de-risks and accelerates the next.

This is the essence of Flagship's model. We do not place a single bet on a single molecule or even a single modality. We build platforms designed to produce many solutions, and ecosystems designed to make those platforms valuable together.

The decade ahead

Agriculture must produce more food, on less land, with fewer chemical inputs, for more demanding consumers, against faster-evolving pests — all within the next generation. Synthetic chemistry will remain part of the answer, but it can no longer be the whole answer. The future of crop protection will be biological, precise, programmable, and — critically — plural.

We are supporting Invaio, Terrana, and ENAI while exploring additional platforms because we believe that future is not only necessary but investable, and that the companies best positioned to deliver it are those designed, from inception, to work as a system. Nature does not protect plants with one mechanism. Neither should we.